• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Praxis Precision Medicines Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    6/27/25 4:47:11 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRAX alert in real time by email
    prax-20250626
    FALSE000168954800016895482025-06-262025-06-26

     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    FORM 8-K
    CURRENT REPORT
    Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934
    Date of Report (Date of earliest event reported): June 26, 2025
    PRAXIS PRECISION MEDICINES, INC.
    (Exact name of registrant as specified in its charter)
     
    Delaware
    001-39620
    47-5195942
    (State or other jurisdiction
    of incorporation)
    (Commission
    File Number)
    (I.R.S. Employer
    Identification No.)

    Praxis Precision Medicines, Inc.
    99 High Street, 30th Floor
    Boston, Massachusetts 02110
    (Address of principal executive offices, including zip code)
    (617) 300-8460
    (Registrant’s telephone number, including area code)
    Not Applicable
    (Former Name or Former Address, if Changed Since Last Report)
     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
     
    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
     
    Title of each class 
    Trade
    Symbol(s)
     
    Name of each exchange
    on which registered
    Common Stock, $0.0001 par value per share PRAX The Nasdaq Global Select Market
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
    Emerging growth company  ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
     
     


    Item 5.07 Submission of Matters to a Vote of Security Holders.
    On June 26, 2025, Praxis Precision Medicines, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”), at which a quorum was present. The Company held its Annual Meeting to consider and vote on the three proposals set forth below, each of which is described in greater detail in the in the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 30, 2025. The final voting results are set forth below.
    Proposal 1 – Election of Class II Directors
    The Company’s stockholders elected Jeffrey Chodakewitz, M.D. and Merit Cudkowicz, M.D. to serve as Class II members of the Board of Directors of the Company until the Company’s 2028 annual meeting of stockholders and until their respective successors are duly elected and qualified, or until their earlier death, resignation or removal, with the votes cast as follows:
    Class II Director NomineesVotes ForVotes WithheldBroker Non-Vote
    Jeffrey Chodakewitz, M.D.
    14,596,1882,998,186778,152
    Merit Cudkowicz, M.D.
    17,499,30095,074778,152
    Proposal 2 – Ratification of Appointment of Ernst & Young LLP as the Company’s Independent Registered Public Accounting Firm
    The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025, with the votes cast as follows:
    Votes ForVotes AgainstAbstainBroker Non-Vote
    18,358,6367,6306,2600
    Proposal 3 – Advisory Vote on Executive Compensation
    The Company’s stockholders approved, on an advisory (non-binding) basis, the compensation of the Company’s named executive officers, with the votes cast as follows:
    Votes ForVotes AgainstAbstainBroker Non-Vote
    10,671,3206,919,7053,349778,152
    No other matters were submitted to or voted on by the Company’s stockholders at the Annual Meeting.



    SIGNATURE
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
    PRAXIS PRECISION MEDICINES, INC.
    Date: June 27, 2025By: /s/ Marcio Souza
     Marcio Souza
     Chief Executive Officer

    Get the next $PRAX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $PRAX

    DatePrice TargetRatingAnalyst
    6/2/2025$97.00Outperform
    Oppenheimer
    5/7/2025$80.00Buy
    Chardan Capital Markets
    3/3/2025$120.00 → $105.00Buy
    H.C. Wainwright
    2/11/2025$111.00Buy
    Deutsche Bank
    8/5/2024$134.00Outperform
    Oppenheimer
    6/24/2024$145.00Buy
    Needham
    6/18/2024$155.00Buy
    Guggenheim
    5/1/2024$117.00Outperform
    Robert W. Baird
    More analyst ratings

    $PRAX
    SEC Filings

    See more
    • Praxis Precision Medicines Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Praxis Precision Medicines, Inc. (0001689548) (Filer)

      6/27/25 4:47:11 PM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Praxis Precision Medicines Inc.

      SCHEDULE 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)

      6/6/25 12:00:34 PM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Praxis Precision Medicines Inc.

      SCHEDULE 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)

      5/15/25 4:35:30 PM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRAX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Mitchell Dean J

      4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)

      6/27/25 4:55:31 PM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Young William D

      4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)

      6/27/25 4:55:21 PM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Norden Gregory

      4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)

      6/27/25 4:55:11 PM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRAX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer resumed coverage on Praxis Precision Medicines with a new price target

      Oppenheimer resumed coverage of Praxis Precision Medicines with a rating of Outperform and set a new price target of $97.00

      6/2/25 8:54:06 AM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chardan Capital Markets initiated coverage on Praxis Precision Medicines with a new price target

      Chardan Capital Markets initiated coverage of Praxis Precision Medicines with a rating of Buy and set a new price target of $80.00

      5/7/25 8:38:09 AM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright reiterated coverage on Praxis Precision Medicines with a new price target

      H.C. Wainwright reiterated coverage of Praxis Precision Medicines with a rating of Buy and set a new price target of $105.00 from $120.00 previously

      3/3/25 7:53:12 AM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRAX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Desimone Jill bought $25,375 worth of shares (14,500 units at $1.75) (SEC Form 4)

      4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)

      10/10/23 7:41:39 AM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRAX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      BOSTON, July 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on July 1, 2025, the Compensation Committee of Praxis' Board of Directors granted restricted stock unit awards covering an aggregate of 2,100 shares of its common stock to three new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the empl

      7/2/25 5:00:00 PM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      BOSTON, June 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on June 2, 2025, the Compensation Committee of Praxis' Board of Directors granted a restricted stock unit award covering 750 shares of its common stock to one new non-executive employee under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit award was granted as inducement material to the employee's entering into em

      6/4/25 5:00:00 PM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Praxis Precision Medicines to Participate in Upcoming Conferences

      BOSTON, May 20, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be participating in three upcoming investor conferences: Praxis management will be participating in a fireside chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference, taking place at NASDAQ on Tuesday, May 20th, at 9:30am ET. A webcast of the fireside chat will be available through this link.Praxis management will also be participating in the Mizuho

      5/20/25 8:00:00 AM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRAX
    Leadership Updates

    Live Leadership Updates

    See more
    • Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2022 Financial Results

      PRAX-944 Phase 2b Essential1 Study topline results expected in 4Q22; primary endpoint updated to efficacy PRAX-562 Phase 1 study completed, confirming biomarker change and potential for wide therapeutic window Cash and investments of $165.4 million as of June 30, 2022 supports runway into 1Q24 BOSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today provided a corporate update and reported financial results for the second quarter of 2022

      8/8/22 4:01:00 PM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Praxis Precision Medicines Adds Global Business Expertise to Board of Directors with Appointment of Jill DeSimone

      BOSTON, May 23, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the appointment of Jill DeSimone to its board of directors. "We are very excited to have Jill join the Praxis board of directors. She is an ideal fit for the Praxis board with her impressive background as a global business leader for multi-billion-dollar products, unique insights into product strategy and portfolio prioritization, and breadth of experience advocating for excellence

      5/23/22 9:00:00 AM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Praxis Precision Medicines Announces Management Team Appointments

      BOSTON, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today announced the appointment of Megan Sniecinski as chief business officer and provided key updates on members of the executive leadership team. Praxis has promoted Alyssa Wyant to chief regulatory and quality officer and Karl Hansen, Ph.D., to chief technical operations officer. In addition, chief scientific officer and co-founder, Steven Petrou, Ph.D., has decided to fully dedicate his time to Praxis upon stepping

      12/2/21 7:00:00 AM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRAX
    Financials

    Live finance-specific insights

    See more
    • GeneDx Reports Fourth Quarter and Full Year 2024 Financial Results and Issues Guidance for Full Year 2025

      Grew fourth quarter 2024 revenues1 to $95.3 million Expanded fourth quarter 2024 adjusted gross margins1,2 to 70% Generated fourth quarter 2024 adjusted net income2 of $16.8 million FY 2025 revenue guidance of $350M to $360M, exome/genome volume and revenue growth of at least 30% GeneDx to host conference call today at 8:30 a.m. ET GeneDx Holdings Corp. (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the fourth quarter and full year of 2024. "The fourth quarter capped an outstanding year for GeneDx, as we work to end the diagnostic odyssey with earlier intervention using our industry-leading exome and gen

      2/18/25 6:00:00 AM ET
      $BIIB
      $PRAX
      $STOK
      $WGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Retail: Computer Software & Peripheral Equipment
    • Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results

      Interim analysis for Study 1 of Essential3 Phase 3 program for ulixacaltamide in essential tremor (ET) confirmed for Q1 2025; NDA filing anticipated in 2025 Registrational Cohort 2 of EMBOLD study recruiting following unprecedented seizure freedom seen in positive topline EMBOLD results for Cohort 1 in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) Vormatrigine (PRAX-628) on track for topline from POWER1 study in focal epilepsy and RADIANT study in focal and generalized epilepsy in 2025 Maintains runway into 2027 BOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic i

      11/6/24 7:30:00 AM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Praxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024

      BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced it will report its financial results from the third quarter ended September 30, 2024, before the financial markets open on Wednesday, November 6, 2024. The Company will host a live webcast the same morning at 8am ET, which can be accessed by visiting this registration link. This live webcast will also be available through the Events & Presentations page of the Investors + Media se

      11/1/24 8:00:00 AM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRAX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Praxis Precision Medicines Inc.

      SC 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)

      11/14/24 7:53:30 PM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Praxis Precision Medicines Inc.

      SC 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)

      11/14/24 5:50:15 PM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Praxis Precision Medicines Inc.

      SC 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)

      11/14/24 5:46:12 PM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care